Skip to content
This website includes promotional information and is intended for UK healthcare professionals only. This website has been developed and funded by Exeltis UK.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to Exeltis UK Limited by email to pharmacovigilance.uk@exeltis.com

Xonvea® Commercial LP

Comprehensive guide on Xonvea® covering its use, benefits and tolerability profile.

Xonvea® RCOG LP

Discover where Xonvea® fits into the 2024 RCOG guideline for the management of NVP.

More Interesting Tools

Xonvea® Clinical Summary LP

Clinical summary of the randomised placebo control Phase III trial assessing the effectiveness of delayed-release doxylamine and pyridoxine for nausea and vomiting of pregnancy.

Patient Information LP

Offer this useful explanatory guide to your patients who have been prescribed Xonvea®

Health Professional Academy – Managing nausea and vomiting in pregnancy CPD accredited

  • Describe the potential impact of NVP on maternal and fetal health
  • Explain the importance of actively managing NVP

 

MIMS e-learning – Nausea and vomiting in pregnancy: definition, impact and overview of management

  • Define, recognize, and understand the impact of NVP
  • Outline the diagnostic process for NVP.
  • Summarize management strategies for NVP, including lifestyle, complementary, and pharmacological options

 

Contact

Request a call from a Representative

Complete the form with your information to ensure we connect you with the correct local representative.

This is a promotional website developed and funded by Exeltis UK and it is intended for UK healthcare professionals only.

Please confirm whether you are a UK registered healthcare professional by selecting one of the options below: